Liquidia (LQDA) drew fresh attention after the stock climbed 8.2% on Wednesday to close at $87.50, extending a rally that persisted despite skeptical commentary about the strength of the bullish case.

The latest move takes Liquidia’s share price to $89.03, extending a strong run that includes a 20.25% 1 month share price return and 138.62% 3 month share price return, alongside a very large 5 year total shareholder return.

If you are looking beyond Liquidia and want to see what else is moving in healthcare, this is a good moment to scan 39 healthcare AI stocks

After a surge that has taken Liquidia’s stock well beyond recent analyst targets, the debate shifts to whether the rally mostly reflects the story already or if the large implied discount to intrinsic value suggests more upside still to test.

Most Popular Narrative: 23% Overvalued

Compared with the latest narrative fair value estimate of $72.38, Liquidia’s last close at $89.03 sits well above where that framework lines up.

The analysts have a consensus price target of $72.38 for Liquidia based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the more bullish reporting a price target of $109.0, and the more bearish reporting a price target of just $60.0.

Want to see how Liquidia gets from today’s earnings to that higher fair value range? The narrative hinges on rapid top line compounding, sharply higher margins and a re rated earnings multiple, all working together in a tight set of assumptions.

Result: Fair Value of $72.38 (OVERVALUED)

However, the Liquidia story still hinges on favorable legal outcomes and sustained payer support. Either of these factors could shift sentiment quickly if expectations are not met.

Another View on Liquidia’s Valuation

The analyst narrative frames Liquidia as 23% overvalued versus a $72.38 fair value, yet our DCF model presents a very different picture, with the stock trading about 75% below an estimated future cash flow value of $359.56. Which lens do you consider more appropriate for a long term view?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Liquidia for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 38 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Liquidia drawing strong reactions on both the risk and reward side, this is a good time to review the data yourself, firm up your stance, and then weigh the balance of 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Liquidia?

Do not stop with Liquidia. Broaden your watchlist with fresh ideas that match how you like to invest and make sure you are not missing better fits.

• Target stability and resilience by checking companies in the 79 resilient stocks with low risk scores that may better align with your comfort around volatility.
• Hunt for value by scanning the 38 high quality undervalued stocks to see stocks where quality metrics and current pricing appear out of sync.
• Spot overlooked opportunities by reviewing the screener containing 20 high quality undiscovered gems that few investors may be watching closely yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.